BRCA1 and cancer: Here we conducted a Phase II study to evaluate the safety and efficacy of olaparib and durvalumab (O + D) in patients with advanced solid and predominantly rare cancers, harbouring either somatic or germline BRCA1/2, or other HRR gene alterations.